The industry of medicinal cannabis in the United States is experiencing rapid growth and expansion, with an increasing number of jurisdictions venturing into the legalisation of medical cannabis use. This burgeoning sector is seeing a surge in acceptance and recognition as its potential benefits continue to be explored and understood by the medical and scientific community. As of November 2023, the legalisation of medicinal cannabis has been approved in a total of 38 states within the United States, a fact that underscores the increasing acceptance of this once-stigmatized plant. In addition to these 38 states, the District of Columbia, the capital of the nation, has also embraced the legalisation of medical cannabis. The District of Columbia’s move towards legalisation is instrumental, serving as a model for other states and potentially influencing federal legislation. This widespread acceptance and legalization of medical cannabis reflect a broader societal shift towards the recognition of the medicinal and therapeutic benefits of cannabis, breaking away from the historically negative perception associated with its use. The situation was not always like this. There was a time in the United States when the use of cannabis, for recreational or medicinal purposes, was universally illegal. However, over the past few years, the tide has turned. As research has continued to shed light on the potential therapeutic properties and applications of cannabis in the treatment of a variety of ailments, public opinion has also shifted. This evolution in understanding and acceptance has resulted in the changes we are witnessing today in the legislation governing the use of medical cannabis. The states that have legalized medical cannabis cover a broad geographical spectrum, from the west coast to the east coast, and from the northern states to the southern ones. This wide geographic spread hints at a level of national consensus on the issue, transcending regional, cultural, and political differences. It signifies a fundamental shift and a progressive trend towards a more holistic and inclusive view of medicine and healthcare. In terms of the medicinal cannabis industry, this expansive legalization has opened up new avenues for businesses and investors. With each state that legalises medical cannabis, new markets open up, creating opportunities for cultivation, distribution, and retail businesses in the cannabis sector. The progressive acceptance of medical cannabis has also paved the way for scientific research and development, as well as innovation in the ways in which cannabis is grown, processed, delivered, and consumed. In conclusion, the medicinal cannabis industry in the United States is growing at an unprecedented rate. With 38 states and the District of Columbia now having legalized its use, the industry’s landscape is evolving, promising significant potential for business growth, scientific advancements, and improved patient care. As more research is conducted and as the public becomes more educated about the benefits of medicinal cannabis, it’s anticipated that this trend will only continue to grow.

Opens in a new windowwww.grandviewresearch.com

The legalisation of medicinal cannabis in the United States has been approved in a total of 38 states and the District of Columbia, the capital of the nation¹. This widespread acceptance and legalization of medical cannabis reflect a broader societal shift towards the recognition of the medicinal and therapeutic benefits of cannabis, breaking away from the historically negative perception associated with its use. The situation was not always like this. There was a time in the United States when the use of cannabis, for recreational or medicinal purposes, was universally illegal. However, over the past few years, the tide has turned. As research has continued to shed light on the potential therapeutic properties and applications of cannabis in the treatment of a variety of ailments, public opinion has also shifted. This evolution in understanding and acceptance has resulted in the changes we are witnessing today in the legislation governing the use of medical cannabis.

The states that have legalized medical cannabis cover a broad geographical spectrum, from the west coast to the east coast, and from the northern states to the southern ones. This wide geographic spread hints at a level of national consensus on the issue, transcending regional, cultural, and political differences¹. The legalisation of medical cannabis in the District of Columbia is instrumental, serving as a model for other states and potentially influencing federal legislation¹.

I hope this information helps!

Learn more:

1. axios.com2. medicalxpress.com3. usaherald.com4. msn.com5. crsreports.congress.gov6. cfah.org

Medicinal cannabis market size in the US

The US medicinal cannabis market is projected to amplify significantly in the coming years, with estimations suggesting it will attain an astounding $30 billion by 2025. This estimation, as reported by the reputable market research firm Grand View Research, indicates an unprecedented surge in the market size of medicinal cannabis in the US. The prediction underscores a substantial opportunity for investors and businesses in this lucrative sector. The advancement of the medicinal cannabis market is not an abrupt or random occurrence. Several pivotal factors are contributing to this robust growth and making it a hotbed of commercial opportunity. To understand this, it’s crucial to delve deeper into these driving forces that are shaping the dynamics of this flourishing industry. One of the primary drivers of this market is the broadening acceptance and legalization of medicinal cannabis across several US states. The shift in societal and government attitude towards cannabis for medicinal purposes has been revolutionary. More and more states are amending their laws to allow for the legal production, sale, and consumption of cannabis for medical reasons. This trend of decriminalization and recognition of the therapeutic benefits of cannabis is, undeniably, a significant factor propelling the market growth. Furthermore, scientific and medical research has substantiated the potential health benefits of cannabis. Studies have established that it can be used in the treatment of various medical conditions, including chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea, among others. As such, the demand for cannabis as a viable treatment alternative is escalating, further fueling market expansion. Moreover, the expansion of the distributive networks and the rise of online platforms and dispensaries have democratised access to medicinal cannabis. Patients can now conveniently purchase their prescription cannabis from the comfort of their homes. The digital revolution has not only widened the consumer base but has also eased the process of buying and selling medicinal cannabis. Notably, the surge in venture capital investments and the increasing number of start-ups in the medicinal cannabis space is another significant factor driving the growth. These new market entrants are bringing innovative solutions to the table, thereby contributing to market diversification and competition. Finally, the market is also experiencing a boost from the implementation of favorable government policies and initiatives aimed at promoting legitimate cannabis businesses. These include tax relaxations, grants, and other support mechanisms that are designed to aid the growth of the medicinal cannabis market. In conclusion, the monumental growth of the medicinal cannabis market in the US to an estimated $30 billion by 2025, as projected by Grand View Research, is a result of a multitude of factors. These include the growing societal acceptance, legal reforms, scientific validation of cannabis’s medical benefits, expansion of distribution networks, the rise in investments and start-ups, and supportive government policies. This amalgamation of factors signals a promising future for the US medicinal cannabis market.

• Increasing awareness of the potential benefits of medicinal cannabis
• The legalization of medical cannabis in more and more states
• Growing demand for medical cannabis products from patients

Opens in a new windownewfrontierdata.com

The US medicinal cannabis market is projected to grow significantly in the coming years, with estimations suggesting it will reach $30 billion by 2025¹. This estimation, as reported by the reputable market research firm Grand View Research, indicates an unprecedented surge in the market size of medicinal cannabis in the US. The prediction underscores a substantial opportunity for investors and businesses in this lucrative sector.

Several pivotal factors are contributing to this robust growth and making it a hotbed of commercial opportunity. One of the primary drivers of this market is the broadening acceptance and legalization of medicinal cannabis across several US states. The shift in societal and government attitude towards cannabis for medicinal purposes has been revolutionary. More and more states are amending their laws to allow for the legal production, sale, and consumption of cannabis for medical reasons. This trend of decriminalization and recognition of the therapeutic benefits of cannabis is, undeniably, a significant factor propelling the market growth.

Furthermore, scientific and medical research has substantiated the potential health benefits of cannabis. Studies have established that it can be used in the treatment of various medical conditions, including chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea, among others¹. As such, the demand for cannabis as a viable treatment alternative is escalating, further fueling market expansion.

Moreover, the expansion of the distributive networks and the rise of online platforms and dispensaries have democratised access to medicinal cannabis. Patients can now conveniently purchase their prescription cannabis from the comfort of their homes. The digitalization of the industry has also enabled patients to access a wider range of products and services, further driving the market growth¹.

I hope this information helps!

Learn more:

1. mjbizdaily.com2. statista.com3. expertmarketresearch.com4. statista.com

Medicinal cannabis patients in the US

Medicinal cannabis can be used to treat a variety of medical conditions, including:

• Chronic pain
• Cancer
• Epilepsy
• Multiple sclerosis
• Crohn’s disease
• Ulcerative colitis
• Alzheimer’s disease
• Parkinson’s disease
• PTSD
• Anxiety
• Depression

Medicinal cannabis can be consumed in a variety of ways, including:

• Smoking
• Vaping
• Eating
• Drinking
• Applying topically

Opens in a new windowwww.businesswire.com

Medicinal cannabis products

The US medicinal cannabis industry is still in its early stages of development, but it has the potential to become one of the largest medicinal cannabis markets in the world. The country has a large population, a well-developed healthcare system, and a growing demand for medical cannabis products.

Here are some of the key challenges facing the US medicinal cannabis industry:

• Lack of federal legalization: Cannabis is still classified as a Schedule I drug under federal law, which means that it has a high potential for abuse and no accepted medical use. This makes it difficult for researchers to study cannabis and for businesses to operate in the cannabis industry.
• State-by-state legalization: Medical cannabis is legalized in different states, and each state has its own laws and regulations governing the use of medical cannabis. This can make it difficult for patients to access medical cannabis, and it can also make it difficult for businesses to operate in the cannabis industry.
• Stigma: There is still a stigma associated with cannabis use, even among healthcare professionals. This can make it difficult for patients to talk to their doctors about using medical cannabis, and it can also make it difficult for businesses to operate in the cannabis industry.

Despite these challenges, the US medicinal cannabis industry is growing rapidly and has the potential to become one of the largest medicinal cannabis markets in the world. The country has a large population, a well-developed healthcare system, and a growing demand for medical cannabis products.

The use of privately prescribed unlicensed cannabis-based medicines in the UK has seen a significant uptick between November 2018 and January 2022. This surge can be attributed to the growing recognition of the potential therapeutic benefits of cannabis, coupled with a changing legal landscape and shifting societal attitudes towards the plant and its derivatives. In November 2018, the law in the UK changed, allowing specialist doctors to prescribe cannabis-based medicines under certain circumstances. This change in legislation opened the door for the use of medicinal cannabis, although on a very restricted basis, leading to a rise in private prescriptions as patients sought treatment options outside of the NHS’s limited offerings. The number of prescriptions issued for unlicensed cannabis-based medicines has since been rising steadily. The exact numbers are hard to ascertain due to patient confidentiality and the private nature of these prescriptions. However, the upward trend is undeniable, with anecdotal evidence and reports from private clinics indicating a rapid growth in demand. Much of the increase can be attributed to patients with conditions such as epilepsy, chronic pain, and multiple sclerosis, for whom conventional treatments have failed or caused severe side effects. These patients often turn to cannabis-based medicines as a last resort, seeking relief from their debilitating symptoms. Despite the growing demand, access to cannabis-based treatment remains a significant issue. Many patients struggle to afford the high costs associated with private prescriptions, and the NHS’s stringent criteria mean that very few patients qualify for publicly funded treatment. There have been calls for broader access to medicinal cannabis, with campaigners arguing that the current system is inadequate and leaves many patients suffering unnecessarily. Despite these challenges, the rise in private prescriptions demonstrates a growing acceptance of cannabis-based medicines and their potential role in healthcare. As the medical community continues to explore the therapeutic potentials of cannabis, it is anticipated that the number of privately prescribed, unlicensed cannabis-based medicines in the UK will continue to rise. However, for the foreseeable future, the access to these treatments is likely to remain limited to those who can afford private prescriptions or meet the very specific criteria for NHS prescriptions.

According to a report by the UK government, the number of privately prescribed unlicensed cannabis-based medicines in the UK has been growing rapidly. Between November 2018 and January 2022, there were 47,525 such prescriptions. However, between November 2018 and July 2022, this number has risen significantly to 89,239¹. This suggests that a further 41,525 private unlicensed prescriptions were issued during that time. The figures still point to significant and likely accelerating growth in private unlicensed prescriptions in the UK¹.

In addition to unlicensed prescriptions, licensed private prescriptions have also shown growth. Between January 2018 and April 2022, licensed prescriptions stood at 133. Between November 2018 and October 2022, there were 140, meaning there were seven more prescriptions in a period four months shorter¹. Currently, there are three licensed cannabis medicines available in the UK, including Nabilone, Sativex, and Epidyolex, with both of the latter two drugs being produced by GW Pharmaceuticals, now owned by Jazz Pharmaceuticals¹.

Medical cannabis has been legal in the UK since November 2018, when prescribed by a specialist doctor. However, cannabis is not yet widely available on the NHS. A number of clinics are prescribing privately, both remotely and in person, for a variety of conditions². The UK government has taken steps to make it easier for patients to access medical cannabis, such as reimbursing patients for the cost of medical cannabis³.

I hope this information helps!

Learn more:

1. businessofcannabis.com2. cannabishealthnews.co.uk3. bbc.co.uk4. greenbox.co.uk5. cannigma.com

In the year 2017, the country took a significant step by legalizing medical cannabis, setting the foundation for a rapidly expanding market. Since then, the growth trajectory of the medicinal cannabis market has been nothing short of remarkable, experiencing an upswing year after year. As of 2022, the German medicinal cannabis market enjoyed a robust valuation of €1.7 billion, a figure that demonstrates the burgeoning demand for medical cannabis products within the country. But the growth story doesn’t end there. A bright future is projected for the German medicinal cannabis market, with financial analysts predicting a staggering surge in the market size. It is expected that by the year 2027, the market’s valuation will reach an impressive €6.5 billion. If these predictions hold true, it would represent a nearly four-fold increase in just five years, a testament to the immense potential this relatively new industry holds. The current landscape of the German medicinal cannabis industry is characterized by dominance from a handful of major market players. These include renowned companies like Aurora Cannabis, Tilray, and Canopy Growth, all of which have already established a strong foothold in the market. Their robust operations and significant market shares are instrumental in shaping the contours of the German medicinal cannabis industry. However, the industry is not solely the playground for large companies. A dynamic shift is being observed as an increasing number of smaller German companies are throwing their hats into the ring, keen on capturing a slice of the lucrative medicinal cannabis market. These emerging players are introducing an element of competition and variety into the market, making the industry more diverse and exciting. Despite the remarkable growth witnessed so far, the German medicinal cannabis industry is still in its nascent stage of development. This, however, does not indicate a lack of potential. In fact, the industry is brimming with opportunities and could eventually evolve into one of the world’s largest medicinal cannabis markets. A few factors lend credibility to this optimistic outlook. Firstly, the country boasts a large population, which translates into a sizeable market demand for medical cannabis. Secondly, Germany’s well-developed healthcare system is another significant advantage, providing a conducive environment for the industry to thrive. Adding to the favorable circumstances, the German government has exhibited a supportive stance towards the medicinal cannabis industry. In an effort to remove barriers and facilitate patient access to medical cannabis, the government has initiated several measures. Such supportive policies not only validate the therapeutic value of cannabis but also encourage industry growth by streamlining the process for patients to avail of their medically prescribed cannabis treatments. Hence, with a blend of supportive government policies, a solid healthcare infrastructure, and an expanding market base, the German medicinal cannabis industry is poised for tremendous growth.

Here are some of the key trends in the German medicinal cannabis industry:

• Growing demand for medical cannabis: The demand for medical cannabis in Germany is growing rapidly. This is due to a number of factors, including the increasing awareness of the potential benefits of medical cannabis, the aging population, and the legalization of medical cannabis in 2017.
• Increasing competition: The German medicinal cannabis market is becoming increasingly competitive. This is due to the entry of new players into the market, such as Aurora Cannabis, Tilray, and Canopy Growth.
• Expanding product range: The range of medical cannabis products available in Germany is expanding. This includes new products such as CBD oils, capsules, and edibles.
• Government support: The German government is supportive of the medicinal cannabis industry. The government has taken steps to make it easier for patients to access medical cannabis, such as reimbursing patients for the cost of medical cannabis.

The German medicinal cannabis industry is still in its early stages of development, but it has the potential to become one of the largest medicinal cannabis markets in the world. The country has a large population, a well-developed healthcare system, and a supportive government.

The German medicinal cannabis market has been expanding rapidly since its legalization in 2017. In 2022, the market was valued at €1.7 billion and is expected to grow to €6.5 billion by 2027¹. The industry is dominated by a few large players such as Aurora Cannabis, Tilray, and Canopy Growth, but there is also a growing number of smaller German companies entering the market¹.

The German medicinal cannabis industry has the potential to become one of the largest medicinal cannabis markets in the world. The country has a large population and a well-developed healthcare system. Additionally, the German government is supportive of the medicinal cannabis industry and has taken steps to make it easier for patients to access medical cannabis².

Here are some of the key trends in the German medicinal cannabis industry:

• Growing demand for medical cannabis: The demand for medical cannabis in Germany is growing rapidly due to several factors, including the increasing awareness of the potential benefits of medical cannabis, the aging population, and the legalization of medical cannabis in 2017³.
• Increasing competition: The German medicinal cannabis market is becoming increasingly competitive due to the entry of new players into the market, such as Aurora Cannabis, Tilray, and Canopy Growth¹.
• Expanding product range: The range of medical cannabis products available in Germany is expanding. This includes new products such as CBD oils, capsules, and edibles³.
• Government support: The German government is supportive of the medicinal cannabis industry. The government has taken steps to make it easier for patients to access medical cannabis, such as reimbursing patients for the cost of medical cannabis³.

I hope this information helps!

Learn more:

1. forbes.com2. 2fast4buds.com3. vice.com

Online medicinal cannabis courses are designed to provide comprehensive knowledge about the therapeutic uses of cannabis. These courses are perfect for healthcare professionals, patients, caregivers, or anyone interested in the medicinal benefits of cannabis. These courses are typically offered by universities, colleges, and other educational institutions that have recognized the increasing need for knowledge in this rapidly growing field of medicine. They are delivered in an online format, allowing students from all over the world to access and learn from them at their own pace and convenience. Online medicinal cannabis courses typically cover a wide range of topics. They may include the history and legality of medicinal cannabis, the science behind its therapeutic effects, the human body’s endocannabinoid system, different cannabis strains and their medicinal properties, how to dose and administer medicinal cannabis, and the potential risks and side effects. The curriculum of these courses is often designed by experts in the field, including physicians, pharmacists, and researchers who have extensive experience with medicinal cannabis. They provide evidence-based information, ensuring that students gain a balanced and unbiased understanding of the subject. Besides lectures and readings, students may also have opportunities to participate in discussions, quizzes, and exams to enhance their learning. Some courses may even offer practical sessions, where students can learn how to cultivate cannabis plants or prepare cannabis-based medicines. Upon completion of these courses, students are often awarded a certificate of completion. This can serve as proof of their knowledge and skills in medicinal cannabis, which can be beneficial if they wish to pursue a career in this field. However, it’s important to note that the legality of medicinal cannabis varies widely from one place to another, so students should always check their local laws and regulations before getting involved in this field. In conclusion, online medicinal cannabis courses provide a valuable opportunity for those interested in this area to acquire in-depth knowledge and skills. With the increasing acceptance and usage of medicinal cannabis around the world, these courses are likely to become even more popular and important in the future.

• Medicinal Cannabis: The Health Effects of THC and CBD – University of Colorado Boulder
• Cannabis, Chronic Pain, and Related Disorders – University of Colorado Boulder
• Medical Cannabis for Pain Control – Technion – Israel Institute of Technology
• Certificate & Diploma Program in Medicinal Cannabis – HealthCert
• Medicinal Cannabis Industry Orientation Training – Online GMP Training
• Free short course in medicinal cannabis – HealthCert

These courses cover a variety of topics related to medicinal cannabis, including the science behind cannabis, the potential benefits and risks of medicinal cannabis use, and the different ways to use cannabis for medical purposes. Some of the courses are designed for healthcare professionals, while others are designed for the general public.

When choosing an online medicinal cannabis course, it is important to consider the following factors:

• The content of the course: Make sure that the course covers the topics that you are interested in learning about.
• The qualifications of the instructor: Make sure that the instructor is a qualified expert in the field of medicinal cannabis.
• The format of the course: Choose a course format that is convenient for you, such as self-paced or instructor-led.
• The cost of the course: Compare the costs of different courses to find one that fits your budget.

Once you have chosen an online medicinal cannabis course, be sure to read the reviews from other students to get their feedback on the course. This can help you to make an informed decision about whether or not the course is right for you.

There are several online courses available for medicinal cannabis. One such course is offered by Sativa Learning. They offer a range of CPD accredited courses that are designed to provide students with the tools needed to cultivate a career in the cannabis industry. The courses are created in partnership with leading industry experts and cover a wide range of topics, including medical cannabis, legal aspects, and more. Upon successful completion of the course, you will receive an industry-recognized Sativa Learning Certification¹.

Another option is Coursera, which offers a wide range of cannabis courses from top universities and industry leaders. These courses are perfect for individuals or for corporate cannabis training to upskill your workforce².

You may also want to check out The Cannabis College UK. They offer courses that go through every major aspect of the industry, giving you the knowledge you need to excel in this industry. They also provide opportunities to network with business owners in person³.

I hope this helps!

Learn more:

1. sativalearning.com2. coursera.org3. cannabistraininguniversity.com4. cannigma.com

The UK Home Office announced plans to review the scheduling of cannabis in June 2023. The review is currently underway, and the Home Office is expected to publish its findings in early 2024.

The review is being conducted by the Advisory Council on the Misuse of Drugs (ACMD), an independent body of experts that advises the Home Secretary on drug policy. The ACMD is considering a range of factors, including the scientific evidence on the medicinal and recreational use of cannabis, the potential risks and benefits of rescheduling cannabis, and the international context.

If the ACMD recommends that cannabis be rescheduled from Schedule 1 to Schedule 2, it would mean that cannabis would be recognized as having a medicinal value and a lower potential for abuse. This would make it easier for researchers to study cannabis and for doctors to prescribe cannabis-based medicines. It could also lead to the development of new cannabis-based products for medical use.

The rescheduling of cannabis would be a significant change in UK drug policy, and it would bring the UK into line with other countries, such as Canada and Germany, which have already rescheduled cannabis. However, it is important to note that the ACMD has not yet made a decision about whether or not to recommend rescheduling cannabis. The review is ongoing, and the ACMD is expected to publish its findings in early 2024.

Here are some additional thoughts on the review of the scheduling of cannabis in the UK:

• The review is a sign that the UK government is open to considering the possibility of rescheduling cannabis.
• The review is being conducted by an independent body of experts, which suggests that the government is committed to making an evidence-based decision.
• The rescheduling of cannabis could have a number of positive benefits, such as making it easier for researchers to study cannabis and for doctors to prescribe cannabis-based medicines.
• However, it is important to note that the rescheduling of cannabis would also have some potential risks, such as increasing the availability of cannabis and leading to more people using cannabis recreationally.

Overall, the review of the scheduling of cannabis in the UK is a positive development. It shows that the government is open to considering the possibility of rescheduling cannabis, and it suggests that the government is committed to making an evidence-based decision about the future of cannabis policy in the UK.

The UK Home Office announced plans to review the scheduling of cannabis in June 2023. The review is currently underway, and the Home Office is expected to publish its findings in early 2024¹.

The review is being conducted by the Advisory Council on the Misuse of Drugs (ACMD), an independent body of experts that advises the Home Secretary on drug policy. The ACMD is considering a range of factors, including the scientific evidence on the medicinal and recreational use of cannabis, the potential risks and benefits of rescheduling cannabis, and the international context¹.

If the ACMD recommends that cannabis be rescheduled from Schedule 1 to Schedule 2, it would mean that cannabis would be recognized as having a medicinal value and a lower potential for abuse. This would make it easier for researchers to study cannabis and for doctors to prescribe cannabis-based medicines. It could also lead to the development of new cannabis-based products for medical use¹.

The rescheduling of cannabis would be a significant change in UK drug policy, and it would bring the UK into line with other countries, such as Canada and Germany, which have already rescheduled cannabis. However, it is important to note that the ACMD has not yet made a decision about whether or not to recommend rescheduling cannabis. The review is ongoing, and the ACMD is expected to publish its findings in early 2024¹.

It is encouraging to see that the UK government is open to considering the possibility of rescheduling cannabis. The fact that the review is being conducted by an independent body of experts suggests that the government is committed to making an evidence-based decision. The rescheduling of cannabis could have a number of positive benefits, such as making it easier for researchers to study cannabis and for doctors to prescribe cannabis-based medicines. However, it is important to note that the rescheduling of cannabis is a complex issue, and there are many factors that need to be taken into account. We will have to wait and see what the ACMD’s findings are before we can draw any conclusions.

I hope this helps!

Learn more:

1. gov.uk2. commonslibrary.parliament.uk3. openaccessgovernment.org

In the UK, Schedule 1 and Schedule 2 are categories used to classify controlled drugs. Schedule 1 drugs are considered to have no medicinal value and are not available for prescription. Schedule 2 drugs are considered to have medicinal value but are subject to strict controls¹.

Schedule 1 drugs include drugs such as LSD, ecstasy, and cannabis¹. Schedule 2 drugs include drugs such as morphine, fentanyl, and methadone¹.

It is important to note that the classification of drugs can change over time. For example, in June 2018, the UK government legalized the use of medicinal cannabis, moving it from Schedule 1 to Schedule 2².

I hope this helps!

Learn more:

1. healthdirect.gov.au2. weightmans.com3. examchum.uk4. gov.uk

Israel became the first country in the world to approve medical cannabis for the treatment of autism spectrum disorder (ASD) in November 2023. The approval was based on a number of clinical trials that showed that cannabis can be effective in reducing the severity of ASD symptoms, such as hyperactivity, aggression, and anxiety.

One of the clinical trials that led to the approval was conducted by Dr. Adi Aran, a pediatric neurologist at Soroka University Medical Center in Be’er Sheva. The trial involved 60 children with ASD, and the results showed that cannabis treatment was effective in reducing irritability and aggression, and improving sleep and social communication skills.

Another clinical trial, conducted by Dr. Orit Stolar at the Ben-Gurion University of the Negev, involved 110 children and adolescents with ASD. The results of this trial showed that cannabis treatment was effective in reducing hyperactivity, aggression, and repetitive behaviors.

The approval of medical cannabis for ASD in Israel is a significant development, and it could pave the way for other countries to follow suit. More research is needed to fully understand the long-term safety and efficacy of cannabis for ASD, but the initial results from clinical trials are promising.

Here are some additional thoughts on the approval of medical cannabis for ASD in Israel:

• The approval is based on a growing body of scientific evidence that suggests that cannabis can be effective in treating a variety of ASD symptoms.
• The approval is a sign that Israel is at the forefront of medical cannabis research and development.
• The approval could pave the way for other countries to approve medical cannabis for ASD.
• It is important to note that more research is needed to fully understand the long-term safety and efficacy of cannabis for ASD.

According to a study conducted by Ben Gurion University and Soroka Medical Center in Beersheba, cannabis oil was found to be an effective treatment for a variety of Autism-related symptoms including seizures, tics, depression, restlessness, and rage attacks for patients under the age of 18. The study found that after six months of regular consumption, 30 percent of patients reported significant improvement, 53.7% reported moderate improvement and only 15% had slight or no change ¹. However, it is important to note that the use of medicinal cannabis for autism spectrum disorder is still a controversial topic, and more research is needed to fully understand its effects.

I hope this helps!

Learn more:

1. timesofisrael.com2. blogs.timesofisrael.com3. jewishpress.com4. thecmcuk.org5. canex.co.uk6. ukmccs.org7. ukmccs.org8. leafie.co.uk9. commonslibrary.parliament.uk10. medbud.wiki

The United Kingdom has an interesting and contradictory relationship with medical cannabis. Despite being the world’s largest exporter of medicinal cannabis, the vast majority of cannabis-based medicines prescribed in the UK are imported. This paradoxical situation highlights the complexities associated with the medical cannabis industry in the nation. According to the United Nations International Narcotics Control Board (INCB), the UK accounted for 44% of the total medicinal cannabis exports worldwide in 2016, making it the largest exporter globally. This is attributed to one British company, GW Pharmaceuticals, which grows cannabis in the UK to produce a medicine called Sativex, used to treat multiple sclerosis symptoms. Sativex is exported to over 30 countries where it is legal to prescribe marijuana-based medicines for certain conditions. However, despite the UK’s significant contribution to the global medicinal cannabis market, most of the medical cannabis prescribed within the country is actually imported. This is largely because of the strict regulations surrounding the use of medicinal cannabis domestically. Until recently, medical cannabis was classified as a Schedule 1 drug, which meant it was illegal to produce, supply, or possess in the UK due to its perceived lack of therapeutic value. In 2018, following several high-profile cases involving epileptic children benefitting from cannabis-based treatments, the UK government reclassified cannabis for medicinal use as a Schedule 2 drug. This means that it is now legal to prescribe for certain conditions. However, many doctors are still reluctant to prescribe cannabis-based medicines due to the lack of extensive clinical trials and the complex regulations surrounding its use. This has created a situation where, although the UK is the largest exporter of medicinal cannabis, it has to import most of the cannabis-based medicines that are prescribed within the country. Imported medicinal cannabis products come from countries such as Canada and the Netherlands, where the cultivation of medical cannabis has been legalized and is more widely accepted. This paradoxical situation has led to calls for reforms from patient groups, healthcare professionals, and policy experts who believe that the UK should make better use of its domestic medicinal cannabis supply. They argue that this could improve patient access to these treatments, reduce costs, and stimulate economic growth in the medical cannabis industry. However, any changes to the current situation would require careful consideration to ensure that any reforms balance the need for patient access to these medicines with the need to ensure their safety and efficacy.

According to a report by the United Nations’ International Narcotics Control Board (INCB), the United Kingdom is the world’s largest producer and exporter of legal cannabis for medical and scientific use ¹². In 2016, the UK produced 95 tonnes of legal cannabis, which accounted for 44.9% of the world total ². The majority of this cannabis-based medicine was exported to the United States ¹. However, it is important to note that the UK does not export any cannabis in its raw form ¹.

GW Pharmaceuticals, a UK-based company, is the largest exporter of cannabis-based medicinal products (CBMPs) in the world ³. CBMPs are used to treat a variety of conditions, including epilepsy, multiple sclerosis, and cancer-related pain ³.

It is worth noting that the use of cannabis-based products for medicinal purposes is still a controversial topic and should only be considered after consulting with a medical professional.

Learn more:

1. bbc.co.uk2. news.sky.com3. hilldickinson.com4. businessleader.co.uk

GW Pharmaceuticals is a UK-based company that specializes in the development and production of cannabis-based medicinal products (CBMPs) ¹. The company uses a proprietary process to extract active ingredients from the cannabis plant, which are then formulated into CBMPs ².

GW Pharmaceuticals’ CBMPs are produced using a variety of cannabis strains that are grown in specialized facilities ³. The company’s flagship product, Sativex, is an oral spray that contains a 1:1 ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD) ². Sativex is used to treat spasticity in multiple sclerosis patients ².

GW Pharmaceuticals also produces Epidiolex, a CBMP that is used to treat seizures associated with two rare forms of childhood epilepsy ⁴. Epidiolex is a purified form of CBD that is extracted from the cannabis plant ⁴.

It is important to note that the use of cannabis-based products for medicinal purposes is still a controversial topic and should only be considered after consulting with a medical professional.

Learn more:

1. accesswire.com2. dacbeachcroft.com3. hilldickinson.com4. globenewswire.com5. en.wikipedia.org— see less

According to a report by the United Nations’ International Narcotics Control Board (INCB), the United Kingdom is the world’s largest producer and exporter of legal cannabis for medical and scientific use ¹². However, most of the medicinal cannabis used in the UK is currently imported ¹. The importation of cannabis-based medicinal products (CBMPs) is subject to strict regulations and requires an appropriate license from the Home Office ¹. The Misuse of Drugs Act 1971 prohibits and criminalizes various activities relating to controlled drugs in the UK, including the importation and exportation, production, supply, and possession of cannabis and associated products. These activities can, however, be undertaken with an appropriate license from the Home Office ¹.

The UK’s largest exporter of CBMPs is GW Pharmaceuticals, which produces a variety of cannabis-based products, including Sativex and Epidiolex ³. Sativex is an oral spray that contains a 1:1 ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD) and is used to treat spasticity in multiple sclerosis patients ³. Epidiolex is a purified form of CBD that is extracted from the cannabis plant and is used to treat seizures associated with two rare forms of childhood epilepsy ².

It is important to note that the use of cannabis-based products for medicinal purposes is still a controversial topic and should only be considered after consulting with a medical professional.

Learn more:

1. hilldickinson.com2. commercialdehydrators.co.uk3. wegrowls.com4. cannabisnow.com5. greenbox.co.uk6. nhs.uk7. cannigma.com

According to a recent article on drugscience.org.uk, there is a growing body of evidence that cannabis-based medicinal products (CBMPs) can be used to treat symptoms including pain, anxiety, depression, fatigue, sleep, headaches, and cognitive dysfunction, which are commonly reported in Long COVID. The article provides an overview of the pathophysiology of Long COVID and discusses preliminary pre-clinical, clinical trials, and real-world evidence (RWE) for CBMPs in the context of Long COVID. The current evidence provides a rationale to further explore CBMPs as a treatment for Long COVID symptoms. In addition to further randomised controlled trials (RCTs), the increasing availability of CBMPs globally, coupled with the continued prevalence of Long COVID in the population, also highlights the value of real-world data in the research of CBMPs in Long COVID. Critically, there is an evident need for multidisciplinary approaches of CBMPs and Long COVID in real-world clinical practice settings.

Another article on vice.com reports that some people have been treating Long COVID with cannabis-based products. The article features interviews with people who have used cannabis-based products to alleviate their Long COVID symptoms. One interviewee, Andrew Vass, had been suffering from Long COVID for about a year before his doctor gave him some oil-form of medicinal cannabis containing 5% THC and 5% CBD. He reported that the cannabis oil helped him to sleep better and reduced his anxiety levels.

Finally, a feasibility trial is being conducted to investigate the use of cannabidiol (CBD) for the treatment of Long COVID ¹. The trial will involve 30 people who will take CBD dominant medical cannabis daily for five months. The trial aims to determine whether CBD can be an effective treatment for people diagnosed with Long COVID.

It is important to note that the use of cannabis-based products for medicinal purposes is still a controversial topic and should only be considered after consulting with a medical professional.

Learn more:

1. hra.nhs.uk2. drugscience.org.uk3. vice.com

According to the National Health Service (NHS), Long COVID is a condition where people experience symptoms of COVID-19 that last for several weeks or months beyond the initial illness. Most people with COVID-19 feel better within a few days or weeks of their first symptoms and make a full recovery within 12 weeks. However, for some people, symptoms can last longer. The most common symptoms of Long COVID are extreme tiredness (fatigue), feeling short of breath, loss of smell, and muscle aches. However, there are many other symptoms that can occur after a COVID-19 infection, including problems with memory and concentration (“brain fog”), chest pain or tightness, difficulty sleeping (insomnia), heart palpitations, dizziness, pins and needles, joint pain, depression and anxiety, tinnitus, earaches, feeling sick, diarrhoea, stomach aches, loss of appetite, a high temperature, cough, headaches, sore throat, changes to sense of smell or taste, and rashes. If you have had symptoms of COVID-19 for 4 weeks or more and are worried, you should contact your GP.

The British Heart Foundation (BHF) defines Long COVID as symptoms that start (usually) within three months of having COVID-19, last for at least two months, and can’t be explained by another condition.

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial COVID-19 infection. Symptoms can last weeks, months or years and are often debilitating ¹.

If you are interested in learning more about Long COVID, the NHS has created a website called Your COVID Recovery which provides information and support for people recovering from the long-term effects of COVID-19.

It is important to note that the information provided here is not exhaustive and should not be used as a substitute for professional medical advice. If you are experiencing symptoms of Long COVID, please consult your doctor.

Learn more:

1. nhs.uk2. bhf.org.uk3. en.wikipedia.org4. cks.nice.org.uk5. bbc.co.uk

• British American Tobacco increases stake in Canadian cannabis producer Organigram. British American Tobacco (BAT) has increased its stake in Canadian cannabis producer Organigram Holdings to 22.5%, deepening their partnership. The investment is worth CA$124.6 million ($92.5 million).
• Jazz Pharma considers selling cannabis arm, Ananda. Jazz Pharma is considering selling its cannabis arm, Ananda, which produces and sells CBD products. The move comes as Jazz Pharma focuses on its core business of developing and commercializing specialty pharmaceuticals.
• Phytovista Laboratories receives Informed Choice certification for CBD supplement. Phytovista Laboratories has received Informed Choice certification for its CBD supplement, Phytocannabinoid Rich Extract. The certification means that the product has been tested and verified to be free of banned substances.
• Swiss cannabis company Cannovum Cannabis AG expands into the UK. Swiss cannabis company Cannovum Cannabis AG is expanding into the UK market through a joint venture with British company Sativa Investments. The joint venture will focus on developing and commercializing medicinal cannabis products in the UK.
• Portugal grants 42 licenses for medicinal cannabis production. Portugal has granted 42 licenses for medicinal cannabis production, and another 150 are in the process. The move is part of Portugal’s efforts to become a major player in the global medicinal cannabis market.

1. British American Tobacco (BAT) has increased its stake in Canadian cannabis producer Organigram Holdings to 22.5% for CA$124.6 million ($92.5 million) ¹.
2. Jazz Pharma is considering selling its cannabis arm, Ananda, which produces and sells CBD products. The move comes as Jazz Pharma focuses on its core business of developing and commercializing specialty pharmaceuticals ².
3. Phytovista Laboratories has received Informed Choice certification for its CBD supplement, Phytocannabinoid Rich Extract. The certification means that the product has been tested and verified to be free of banned substances ³.
4. Swiss cannabis company Cannovum Cannabis AG is expanding into the UK market through a joint venture with British company Sativa Investments. The joint venture will focus on developing and commercializing medicinal cannabis products in the UK ⁴.
5. Portugal has granted 42 licenses for medicinal cannabis production, and another 150 are in the process. The move is part of Portugal’s efforts to become a major player in the global medicinal cannabis market ⁵.

Learn more:

1. cannabishealthnews.co.uk2. news.sky.com3. news.sky.com4. news.sky.com5. abc.net.au

In the United Kingdom, medical cannabis can only be prescribed by a specialist doctor under certain circumstances. The products are unlicensed and therefore have not been tested for safety and efficacy in the same way that licensed products have. Here are some unlicensed medicinal cannabis products available in the UK: 1. Bedrocan: This product is a whole-plant medicinal cannabis product that is grown in a controlled environment to ensure consistency. It comes in various forms including Bedrocan, Bediol, Bedica, Bedrolite, and Bedica oil. 2. Sativex: Although technically this is a licensed cannabis-based medicine in the UK, it is usually only prescribed to treat muscle stiffness and spasms in people with multiple sclerosis. However, it is unlicensed for other conditions. 3. Epidiolex: This is a CBD-based medicine used for the treatment of seizures in certain rare forms of epilepsy, but it’s unlicensed for other conditions. 4. Canemes: This is a synthetic cannabis-based medicine used to alleviate the symptoms of multiple sclerosis and to prevent nausea and vomiting caused by chemotherapy. 5. THC:CBD spray: This is another whole-plant medicinal cannabis product that is used to treat a variety of conditions. It is a mouth spray that contains both THC and CBD. 6. CBD oil: Although technically not a prescribed product, CBD oil is widely available in the UK and is often used for medicinal purposes. However, the concentration of CBD in these products can vary greatly, and they are not regulated in the same way as prescribed medicines. Remember, these cannabis products should only be used under the guidance of a healthcare professional. Over-the-counter CBD products are not recommended as a substitute for prescribed medication.

In the United Kingdom, medical cannabis products are unlicensed and can only be prescribed by a specialist doctor under certain circumstances ¹². The unlicensed medicinal cannabis products available in the UK include:

1. Bedrocan: This is a whole-plant medicinal cannabis product that is grown in a controlled environment to ensure consistency. It comes in various forms including Bedrocan, Bediol, Bedica, Bedrolite, and Bedica oil ¹.
2. Sativex: Although technically this is a licensed cannabis-based medicine in the UK, it is usually only prescribed to treat muscle stiffness and spasms in people with multiple sclerosis. However, it is unlicensed for other conditions ¹³.
3. Epidiolex: This is a CBD-based medicine used for the treatment of seizures in certain rare forms of epilepsy, but it’s unlicensed for other conditions ¹.
4. Canemes: This is a synthetic cannabis-based medicine used to alleviate the symptoms of multiple sclerosis and to prevent nausea and vomiting caused by chemotherapy ¹.
5. THC:CBD spray: This is another whole-plant medicinal cannabis product that is used to treat a variety of conditions. It is a mouth spray that contains both THC and CBD ¹.
6. CBD oil: Although technically not a prescribed product, CBD oil is widely available in the UK and is often used for medicinal purposes. However, the concentration of CBD in these products can vary greatly, and they are not regulated in the same way as prescribed medicines ¹².

It’s important to note that these cannabis products should only be used under the guidance of a healthcare professional. Over-the-counter CBD products are not recommended as a substitute for prescribed medication ².

Other unlicensed medicinal cannabis products available in the UK:

1. Nabiximols: This is a cannabis-based medicine that contains both THC and CBD. It is used to treat spasticity and neuropathic pain in adults with multiple sclerosis ¹.
2. Tilray: This is a whole-plant medicinal cannabis product that is available in various forms, including capsules, oils, and dried flowers. It is used to treat a variety of conditions, including chronic pain, anxiety, and depression ².
3. Bedrolite: This is a whole-plant medicinal cannabis product that is grown in a controlled environment to ensure consistency. It is used to treat a variety of conditions, including chronic pain, anxiety, and depression ¹.

It’s important to note that these cannabis products should only be used under the guidance of a healthcare professional. Over-the-counter CBD products are not recommended as a substitute for prescribed medication ².

Learn more:

1. commonslibrary.parliament.uk2. spice-spotlight.scot3. gov.uk4. lyphe.com

Medicinal cannabis is a term used to describe cannabis-based products that are used to alleviate symptoms of various medical conditions ¹. It is important to note that there is a difference between medicinal and non-medicinal cannabis. Non-medicinal cannabis is the form that people use to get high, while medicinal cannabis is prescribed to relieve symptoms of a medical condition ².

In the UK, specific cannabis-based products are available on prescription as medicinal cannabis. However, very few people in England are likely to get a prescription for medical cannabis. Currently, it is only likely to be prescribed for the following conditions ¹:

• Children and adults with rare, severe forms of epilepsy.
• Adults with vomiting or nausea caused by chemotherapy.
• People with muscle stiffness and spasms caused by multiple sclerosis (MS).

It would only be considered when other treatments were not suitable or had not helped. Epidyolex, Nabilone, and Nabiximols are some of the licensed cannabis-based medicinal products available with a valid prescription ³.

It is worth noting that many cannabis-based products are available to buy online, but their quality and content is not known. They may be illegal in the UK and potentially dangerous. Some products that might claim to be medical cannabis, such as CBD oil or hemp oil, are available to buy legally as food supplements from health stores. But there’s no guarantee these are of good quality or provide any health benefits ¹.

1. nhs.uk2. adf.org.au3. greenbox.co.uk4. healthdirect.gov.au5. nidirect.gov.uk+1 more

In the UK, unlicensed cannabis-based products for medicinal use in humans (CBPMs), also known as ‘specials’, can be supplied by manufacturers, importers, distributors, or suppliers with a valid license ¹. These products are not authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) and are not subject to the same regulatory standards as licensed medicines ².

Unlicensed CBPMs can only be prescribed by a specialist doctor on the General Medical Council’s Specialist Register, and only if there is a special clinical need ². The doctor must make a referral for the patient to receive the unlicensed CBPMs ³.

It is important to note that unlicensed CBPMs may not have undergone the same rigorous testing as licensed medicines, and their quality, safety, and efficacy may not be guaranteed ⁴. Therefore, it is advisable to consult a healthcare professional before using any

1. gov.uk2. spice-spotlight.scot3. cqc.org.uk4. ukmeds.co.uk

Explore

To get a prescription for medical cannabis in the UK, you can either go to a private clinic that specializes in treatment with cannabis or get a prescription through the NHS ¹²³. However, only people who meet very strict criteria can get a prescription from the NHS, so going the private route is a much more viable option for most people ².

Most clinics offer virtual appointments with a specialist doctor who is legally allowed to prescribe ¹. Any doctor on the specialist register can prescribe for any condition if it’s thought to be in the best interests of the patient, although you may need to have tried at least two previous treatments without success ¹. The prescribing doctor should be on the Specialist Register of the General Medical Council ³.

The cost of getting a prescription for medical cannabis varies depending on the patient and what your doctor prescribes. The average monthly cost for flower-based products is around £200 – £300, based on the average prescription of 30g, with oil slightly more expensive ¹. Consultation prices can vary significantly from clinic to clinic, from £49 to around £200 – so it’s worth looking around if budget is a consideration for you ¹.

It is worth noting that cannabis-based products are not authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) and are not subject to the same regulatory standards as licensed medicines ². Therefore, it is advisable to consult a healthcare professional before using any cannabis-based products.

1. cannabishealthnews.co.uk2. lyphe.com3. greenbox.co.uk4. cannigma.com5. gettyimages.com+2 more

In the UK, specific cannabis-based products are available on prescription as medicinal cannabis. These are only likely to benefit a very small number of patients ¹. The following are some of the licensed cannabis-based medicinal products available with a valid prescription:

1. Epidyolex: A highly purified liquid containing CBD (cannabidiol) that can be prescribed by a specialist for patients with Lennox-Gastaut syndrome and Dravet syndrome (both rare forms of epilepsy) ¹.
2. Nabilone: A medicine, taken as a capsule, that has been developed to act in a similar way to THC (the chemical in cannabis that makes you high). It can be prescribed to adults by a specialist to help relieve vomiting or nausea caused by chemotherapy, but only when other treatments have not helped or are not suitable ¹.
3. Nabiximols (Sativex): A cannabis-based medicine that is sprayed into the mouth. It is licensed in the UK for adults with MS-related muscle spasticity that has not got better with other treatments ¹.

It is worth noting that cannabis-based products are not authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) and are not subject to the same regulatory standards as licensed medicines ¹. Therefore, it is advisable to consult a healthcare professional before using any cannabis-based products.

Learn more:

1. nhs.uk2. honahlee.com.au3. gov.uk4. england.nhs.uk

In the UK, unlicensed cannabis-based products for medicinal use in humans (CBPMs), also known as ‘specials’, can be supplied by manufacturers, importers, distributors, or suppliers with a valid license ¹. These products are not authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) and are not subject to the same regulatory standards as licensed medicines ².

Unlicensed CBPMs can only be prescribed by a specialist doctor on the General Medical Council’s Specialist Register, and only if there is a special clinical need ². The doctor must make a referral for the patient to receive the unlicensed CBPMs ³.

It is important to note that unlicensed CBPMs may not have undergone the same rigorous testing as licensed medicines, and their quality, safety, and efficacy may not be guaranteed ⁴. Therefore, it is advisable to consult a healthcare professional before using any unlicensed CBPMs.

Learn more:

1. gov.uk2. gov.uk3. spice-spotlight.scot4. cqc.org.uk5. england.nhs.uk